AZIENDA OSPEDALIERA UNIVERSITARIA MEYER IRCCS

Their core work

Meyer Children's Hospital in Florence is one of Italy's leading pediatric research hospitals (IRCCS — a nationally recognized scientific institute). Their EU project work centers on improving clinical trials and drug development specifically for children, adolescents, and neonates — a historically underserved population in pharmaceutical research. They also contribute to large-scale efforts in understanding autoimmune diseases and treatment non-response through molecular-level research, and have worked on digital health literacy for European citizens.

What they specialise in

How they've shifted over time

With only three projects spanning 2016–2019 start dates, the evolution is limited but shows a clear trajectory. The earliest project (IC-Health, 2016) focused on patient-facing digital health literacy — a relatively broad public health topic. The later projects (c4c, 2018; 3TR, 2019) shift decisively toward molecular medicine, clinical trial infrastructure for children, and precision approaches to autoimmune disease, reflecting a move toward deeper, more specialized clinical research.

Meyer is moving toward specialized pediatric clinical research infrastructure and molecular-level disease understanding, making them increasingly valuable for consortia needing pediatric expertise in precision medicine.

How they like to work

Meyer operates exclusively as a participant or third party — never as coordinator — which is typical for a clinical institution contributing domain expertise rather than managing large consortia. They work in very large consortia (145 unique partners across 22 countries), indicating comfort with complex multi-national projects. Their role is that of a specialist contributor bringing pediatric clinical access and expertise to broader research networks.

Despite only three projects, Meyer has connected with 145 unique partners across 22 countries, reflecting participation in large pan-European health consortia. Their network is broad rather than deep, spanning most of the EU research landscape in health.

What sets them apart

Meyer's defining advantage is its dual identity: a fully operational pediatric hospital with IRCCS (national scientific research institute) status. This means they offer direct access to pediatric patient populations and clinical settings — something most research-only institutions cannot provide. For any consortium needing real-world pediatric clinical data, trial sites, or neonatal expertise in Italy, Meyer is a natural and credible partner.

Highlights from their portfolio

• c4c
  A flagship European network (running to 2025) building shared infrastructure for pediatric clinical trials — addresses a critical gap in medicines development for children.
• 3TR
  Large-scale project running to 2026 investigating why treatments fail using advanced genomics and single-cell data — Meyer contributes the pediatric disease perspective.